Correlation between @entity1499 pharmacokinetic parameters, and clinical and biological status in XXXX @entity1 .

@entity1 @entity1500 @entity158 @entity1499 @entity309 @entity2693
OBJECTIVE: To determine the correlation between the pharmacokinetic (PK) parameters of @entity1499 ( @entity1500 ), clinical status and laboratory test results in @entity309 ( @entity309 ) @entity1 . METHODS: 22 @entity1 (4 M/18F, mean age: 50 +/- 12 years, mean duration of @entity309 : 8.5 +/- 6.5 years, mean duration on @entity1500 : 8 +/- 10 months) were included in a prospective study. The mean dose of @entity1500 administered was 6 +/- 0.7 mg/m2 of body area/week. No @entity1 received any nonsteroidal antiinflammatory drug (NSAID). Blood and urine samples were collected over 24 hours (9 blood samples). The @entity1500 concentrations were assayed by fluorescence polarization immunoassay. Clinical parameters (Ritchie articular index, morning @entity2693 , @entity158 count, joint swelling count), hematological, liver and renal function tests, and ESR were recorded. Correlations between the @entity1 ' PK parameters, laboratory tests and clinical status were carried out using Pearson's correlation coefficient test. RESULTS: A significant correlation was observed between the Ritchie articular index, morning @entity2693 and the area under the curve (p = 0.009 and p = 0.026, respectively). No correlation was found with the other parameters. CONCLUSION: These results suggest that when the @entity1 's disease activity is higher, the AUC becomes more important, reflecting a greater body exposure to @entity1500 .
